Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-Small Cell Lung Cancer Stage IV”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT02346370
What this trial is testing

A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Halozyme Therapeutics 16
Testing effectiveness (Phase 2)Study completedNCT00004139
What this trial is testing

Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer
Alliance for Clinical Trials in Oncology 80
Large-scale testing (Phase 3)UnknownNCT02859077
What this trial is testing

EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Who this might be right for
Non-Small-Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 100
Not applicableStudy completedNCT00899028
What this trial is testing

Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants

Who this might be right for
Lung Cancer
Vanderbilt University Medical Center 689
Early research (Phase 1)WithdrawnNCT02451865
What this trial is testing

Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer

Who this might be right for
Recurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
Testing effectiveness (Phase 2)Study completedNCT04452877
What this trial is testing

Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 40
Not applicableStudy completedNCT02623257
What this trial is testing

EGFR Mutations on ctDNA in Patients With Advanced NSCLC

Who this might be right for
Non-small Cell Lung Cancer Stage IIINon-Small-Cell Lung Cancer Metastatic
First People's Hospital of Hangzhou 1,055
Not applicableApproved For MarketingNCT06279728
What this trial is testing

Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients

Who this might be right for
EGFRm Advanced Non-Small Cell Lung CancerEGFRm Metastatic Non-Small Cell Lung Cancer
Daiichi Sankyo
Testing effectiveness (Phase 2)Looking for participantsNCT07104630
What this trial is testing

Pulmonary Rehabilitation in Advanced Lung Cancer Survivors

Who this might be right for
Non-small Cell Lung Cancer Stage IIINon-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer+1 more
Case Comprehensive Cancer Center 85
Testing effectiveness (Phase 2)Study completedNCT01378962
What this trial is testing

Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 50
Testing effectiveness (Phase 2)Study completedNCT00271505
What this trial is testing

Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center 43
Post-approval studies (Phase 4)Looking for participantsNCT07357597
What this trial is testing

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

Who this might be right for
Stomatitis
AstraZeneca 100
Post-approval studies (Phase 4)Study completedNCT02316327
What this trial is testing

Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Fundacion Clinic per a la Recerca Biomédica 19
Testing effectiveness (Phase 2)UnknownNCT05141786
What this trial is testing

MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Who this might be right for
Non-small- Cell Lung Cancer (NSCLC)
Shanghai Miracogen Inc. 100
Not applicableStudy completedNCT03271554
What this trial is testing

Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 355
Not applicableStudy completedNCT00579683
What this trial is testing

Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer

Who this might be right for
Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC)
Memorial Sloan Kettering Cancer Center 228
Not applicableUnknownNCT04306094
What this trial is testing

Factors Determining the Prognosis in NSCLC Stage IV

Who this might be right for
NSCLC Stage IV
Instituto do Cancer do Estado de São Paulo 217
Testing effectiveness (Phase 2)Study completedNCT04681131
What this trial is testing

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
BioAtla, Inc. 85
Not applicableActive Not RecruitingNCT04994795
What this trial is testing

Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer Metastatic
Sophia Genetics SAS 4,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT07703228
What this trial is testing

Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC Stage IIIB~IVSecond-line Therapy+1 more
Nanfang Hospital, Southern Medical University 38
Next Page